Download Free Medical Central Nervous System Malignancies PowerPoint Presentation

Central Nervous System Malignancies PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical PowerPoint presentation titled "Central nervous system malignancies".
This medical PowerPoint presentation talks about Central nervous system malignancies.
Central nervous system (CNS) malignancies are cancers that originate in the brain or spinal cord. These tumors can be primary, meaning they start in the CNS, or secondary, meaning they have spread from another part of the body to the CNS.
There are many types of CNS malignancies, but some of the most common include Gliomas, Meningiomas, Pituitary tumors, Medulloblastomas, and Metastatic tumors.
Treatment for CNS malignancies depends on the type of tumor, its size and location, and the patients overall health. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

Tags : Central nervous system malignancies, cancers, Gliomas, Meningiomas, Pituitary tumors, Medulloblastomas, Metastatic tumors, Child Neurology PowerPoint presentation, Neurology PowerPoint presentation

Published on : Mar 21, 2023 | Views : 989 | Downloads : 3

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Central nervous system malignancies
Slide 2-

Commonest malignant solid tumors in childhood 20% of cancers in age < 15 years Annually 20 – 26/ 1 million children below the age of 16 years Age –stratified incidence is: <1year - 27/ 1 million 1 – 4 - 31/ 1 million 5 – 9 - 27/ 1 million 10 – 14 - 20/ 1 million Slightly higher frequency in boys 1.25:1 (especially for medulloblastoma and germinoma) Epidemiology
Slide 3-

Etiology and pathogenesis Association between primary CNS tumors and following conditions/ genetic disorders : 1. Neurofibromatosis (NF) type 1 and 2 2. Tuberous sclerosis 3. Von Hippel- Lindau syndrome 4. Gordlin’s, Cowden’s, Turcot’s syndromes 5. Li-Fraumeni syndrome (mutation of suppressor oncogene p53) Deletion of chromosome 17 or 20 (medulloblastoma) Exposition of the brain to ionizing radiation i.e. after cranial radiotherapy in leukemia
Slide 4-

Pathology Supratentorial lesions (30 – 40%): 1. Cerebral hemisphere ( astrocytoma, ependymoma, glioblastoma, meningioma) 2. Sella or chiasm ( craniopharyngioma, pituitary adenoma, optic nerve glioma) Infratentorial lesions (60 – 70%) 1. Cerebellum (medulloblastoma, astrocytoma, meningioma) 2. Brain stem ( astrocytoma, ependymoma, glioblastoma)
Slide 5-

Classification Based on histogenesis and predominance of cell type Degree of malignancy is defined by grading system e.i. WHO grade based on cellular morphology, mitotic index, anaplasia and necrosis: grades I and II represent benign tumors grades III and IV - malignant tumors
Slide 6-

Clinical presentation Depends on : -age -anatomical site -tumor type -raised intracranial pressure (ICP) -localizing neurological deficits
Slide 7-

Signs of increased ICP Direct tumor infiltration Compression of normal structures Secondary to obstruction of the cerebrospinal fluid (CSF)
Slide 8-

Older children: -inilially behavioural changes and declining school performance prior to development of the more classical features of headache, nausea and vomiting , headaches start as generalized and intermittent > increase in both intensity and frequency with time - the child may awake with headache at night, with the pain generally being worse in the morning and improving during the day with an upright posture -School-age children complain of visual disturbances
Slide 9-

Infants and younger children: plasticity of the developing skull and inability to communicate symptoms > -infant may be irritable, with failure to thrive, associated with anorexia and vomiting -regression of developmental milestones -increase head circumference with widened sutures and a tense anterior fontanelle „sun-setting” sign
Slide 10-

Symptoms and signs according to anatomical site of CNS tumors Supratentorial (30-40%) Cerebral hemisphere- hemiparesis, spasticity, seizures (focal or generalized) - para/suprasellar – endocrinopathy (growth failure, diabetes insipidus, pubertal abnormality) - hypothalamus – diencephalic syndrome (infants), developmental and behavioural abnormalities - optic pathway – visual field acuity, color vision deficits, optic atrophy, nystagmus, head tilt - pineal - Parinaud’s syndrome, sleep abnormalities - thalamus, basal ganglia – pain, sensory loss, memory disturbances - intraventicular - meningeal
Slide 11-

Infratentorial (60 – 70%) - posterior fossa – ataxia, nystagmus, dysmetria (presents as clumsiness or worse handwriting) - brainstem – multiple cranial nerve palsies, hemiparesis, spasticity, mood changes Spinal (2 – 5%) - primary intramedullary – pain (local back and root pain), motor and sensory disturbance - spinal metastases – scoliosis, sphincter (bowel, bladder) disturbances, reflex changes
Slide 12-

Diagnostic evaluation Magnetic resonance and computed tomography – basic imaging techniques for brain tumors Positron emission tomography – help to distinguish tumors or lesions with a volume greater than 1 cm3 Conventional radiography of the skull: bone structure, separating off sutures ( due to ICP), calcification within the brain Special methods (for special indications): - brain scintigraphy - angiography -ultrasonography -myelography
Slide 13-

Additional diagnosis Cerebral fluid analysis ( to determine spread of the tumor to the spinal fluid) Electroencephalography Stereotactic biopsy
Slide 14-

Therapy Neurosurgery for maximum tumor removal and low morbidity depending on the location and extent of the tumor -often preoperative relief of intracranial pressure by ventriculoperitoneal or ventriculoarterial shunt - preoperative reduction of tumor edema by corticosteroids - in patients with seizures - anticonvulsive therapy
Slide 15-

Radiotherapy – extension and volume of irradiation depend on the biology and histology of the tumor, age of the child and combination with chemotherapy and neurosurgery - irradiation in children < 3 years of life only in special cases Chemotherapy – depends on tumor type, location and age -efficacy and penetration depend on vascularization of the tumor
Slide 16-

MR spectra and MR images of medulloblastoma
Slide 17-

8-year-old girl with juvenile pilocytic astrocytoma
Slide 18-

2-year-old boy with atypical teratoid-rhabdoid tumor
Slide 19-

Neuroblastoma
Slide 20-

Malignant, embryonal tumor derived from precursor cells of sympathetic ganglia and adrenal medulla Other types of tumors derived from sympathetic nervous system: -ganglioneuroblastoma -ganglioneuroma -pheochromocytoma Possibility to spontaneous regression and differentiation to benign tumor in infants less 1 year of age extremely malignant in older children
Slide 21-

Epidemiology 8% of all neoplasms in children Most frequent malignant neoplasm in infants Mean age at diagnosis 2 – 5 years
Slide 22-

Pathology Two distinct entities: Infant: 1. possibility of spontaneous regression (apoptosis or differentiation into ganglioneuroblastoma) 2. chemosensitive, chemocurable Older 3. chemoresistant malignancies
Slide 23-

Molecular cytogenetics MYCN oncogene amplification. MYCN is located on chromosome 2p. Independent prognostic factor: in stage III EFS for patients with a single copy is curable 80%; for those with amplification MYCN – 20% DNA ploidy: hyperploidy = good prognosis Nerve growth factor receptor: ligands for high –affinity tyrosine kinase receptors TRKA, TRKB, TRKC: -TRKA expression is associated with MYCN single copy, low stage and good prognosis - TRKA (-) + MYCN amplification= very poor survival Structural and numerical abnormalities of chromosome 1
Slide 24-

Clinical manifestation Occurence in any area with sympathetic nervous system Primary location: -abdomen 65% -adrenal medulla or sympathetic ganglia 46% -posterior mediastinum 15% -pelvic 4% -head and neck 3% -others 8%
Slide 25-

Common symptoms Weight loss Fever Abdominal disturbances Irratability Pain of bones and joints Child not stand up, not walk Pallor Lassitude
Slide 26-

Symptoms associated with catecholamine production Paroxysmal attacks of sweating, flushing, pallor Headache Hypertension Palpitation
Slide 27-

Paraneoplastic syndromes VIP syndrome: untreatable diarrhea,with low level of potassium Opsoclonus- myoclonus Anemia, trombocytopenia, leukopenia ( in bone marrow infiltration or massive hemorrhage)
Slide 28-

Local symptoms Abdomen: -intra-abdominal tumor –paravertebral and presacral -neurological dysfunction -abdominal distension Liver: -hepatomegaly Chest, posterior mediastinum, vertebrae: -compression of trachea > coughing, dyspnea -infiltration in vertebral foramina > dumbbell tumor -compression of nerves >disturbances of gait, muscle weakness, parasthesia, bladder dysfunction, constipation
Slide 29-

Eyes: -periorbital edema, swelling, yellow- brown ecchymoses -proptosis and exophthalmos, strabismus, opsoclonus -papillary edema, bleeding of the retina, atrophy of the optic nerve Neck: -cervical lymphadenopathy -supraclavicular tumor -Horner syndrome: enophthalmos, miosis, ptosis, Raccon eyes
Slide 30-

Skin: - subcutaneous nodules of blue color > reddish > white owing to vasoconstriction from release of catecholamines after palpation - nodules are mainly observed in neonates or infants with disseminated NBL Bone: -pain involvement mainly in the skull and long bones - in X-rays – lytic defects with irregular margins and periosteal reaction Bone marrow: -trombocytopenia, anemia
Slide 31-

Metastases Lymphatic and/or hematogenous spread Often initially present in children (40 – 50% children < 1 year and 70% children > 1 year) Metastatic spread mostly in bone marrow, bone, liver, skin
Slide 32-

2-year-old-girl with abdominal neuroblastoma
Slide 33-

CT image with large abdominal neuroblastoma
Slide 34-

123-MIBG scintscan
Slide 35-

International Staging System for NBL(INSS) 1 - localized tumor with complete excision,lymph nodes negative 2a - localized tumor without incomplete gross excision, representative, ipsilateral nonadherent lymph nodes negative for tumor microscopically 2b – ipsilateral nonadherent lymph nodes positive for tumor. Enlarged contralateral lymph nodes negative microscopically 3 – unresectable unilateral tumor infiltrating across the midline,with or without regional lymph node involvement or localized unilateral tumor with contralateral regional lymph node involvement or – midline tumor with bilateral extension by infiltration or by lymph node involvement 4 – any primary tumor with dissemination to distant lymph nodes, bone, bone marrow, liver, skin or other organs (except as defined for stage 4S 4s localized primary tumor (as defined for stages 1, 2a, 2b) with dissemination limited to skin, liver or bone marrow; limited to infants aged less than 1 year)
Slide 36-

Laboratory findings Tumor markers: -catecholamines: vanillylmandelic acid (VMA), homovanillic acid (HVA) dopamine in urine/ plasma adrenaline, noradrenaline -neuron-specific enolase (glycolitic enzyme of brain and neuroendocrine tissues) -NSE Ferritin Lactate dehydrogenease (LDH) Bone marrow (aspiration and biopsy)
Slide 37-

Locoregional involvement Computed tomography scan and/or Ultrasound and/or magnetic resonance imaging → localize the mass, provide measurements, give anatomical information about intra- and extraperitoneal structures, differentiate cystic from solid tumors, define the extent of a primary tumor and its relationship with other structures, detect small calcification
Slide 38-

Evaluation of metastases Bone marrow metastases – bone marrow aspiration and trephine biopsy Skeletal metastases - X-ray, Tc-99 scintigraphy, mIBG scintigraphy demonstrates primary, residual tumor masses,diffuse bone marrow infiltration, skeletal, lymph node and soft tissue metastases FDG-PET scanning
Slide 39-

Therapy Depends on: age, stage, localization and molecular features at diagnosis Surgery Chemotherapy IV stage Radiotherapy Target radiotherapy (I-131-mIBG) Differentiation therapy (retinoids 13-cis and all-trans) Immunotherapy: anti-GD2 antibodies Auto-BMT
Slide 40-

Prognosis Depends on: -age (favorable if less than 18 months of age at diagnosis), -stage and localization (favorable in primary NBL of thorax, presacral and cervical) -involvement of lymph nodes (poor prognosis) Low-risk group - 90% long-term survival Intermediate and high-risk groups: -response to initial treatment 60-70% of children with complete or partial remission -after consolidation therapy (high-dose chemotherapy+ autologous stem cell support) –EFS after 3 years is 40-60%
Slide 41-

Hepatic tumors
Slide 42-

Malignant: -hepatoblastoma 43% -hepatocellular carcinoma 23% -sarcoma 6% Benign: -vascular (haemangioma,haemangioendothelioma) 13% -hamartoma 6% -others 9%
Slide 43-

Incidence (malignant) -1.2 –5% of all neoplasms in childhood Boys: girls 1.4 –2 :1 High incidence in genetically associated syndromes: -Beckwith-Wiedemann syndrome, familial adematous polyposis, trisomy 18, glycogen storage disease, hereditary tyrosinemia, Li-Fraumeni syndrome HBL –mostly in infants, rarely after the age of 3 years Hepatocellular Ca – in older children, in adolescents, after hepatitis B
Slide 44-

Clinical symptoms Abdominal mass and/ or abdominal distention Anorexia, weight loss Lethargy Jaundice and ascites Abdominal pain Pallor Precocious puberty (hepatoblastoma), virilization (due to gonadotrophin production by the tumor) Generalized osteoporosis (HBL)- tumor cells secrete osteoclast-activating factor
Slide 45-

Laboratory diagnosis Serum AFP elevated in 80 - 90% of children with HBL and in 60-70% with hepatocellular Ca B-HCG elevated in both Increased bilirubin Increased serum aspartate aminotransferase (AST), alanine transaminase (ALT) because of associated hepatitis or cirrhosis Anemia, thrombocytosis, trombocytopenia (rarely) biopsy
Slide 46-

Radiological diagnosis Ultrasound – liver enlarged, displacement of stomach and colon, elevated diaphragm on the right side CT, MRI Liver scintigraphy metastases: chest X-ray, lung CT HBL hepatocellular carcinoma
Slide 47-

Treatment Presurgical chemotherapy (makes HBL resectable) Complete resection (initially > 50% of liver tumors are not totally resectable) Liver transplantation Prognosis: Depends on stage of the tumor after complete tumor resection and chemotherapy 65-75 % children with HBL and 40-60% with hepatocellular Ca survive
Slide 48-

Germ cell tumors (GCT)
Slide 49-

Develop from embryonal germ cells Represent ectodermal, endodermal and mesodermal lineages Approximately 3% of childhood malignancies Annually 2.4 – 3.8/ 1 million/per year 2/3 GCTs in children occur in extragonadal sites The commonest GCT - sacrococcygeal teratoma Bimodal age distribution: one peak in children < 3y ears of age (sacrococcygeal tumors, yolk sac tumors of testis) - the later- the later GCT of the ovary, testis, and intracranial sites
Slide 50-

Histological classification of gonadal and extragonadal tumors Germ cell and germinoma/ dysgerminoma and embryonal yolk sac tumor (pluripotent cells) a)extraembryonic structures - yolk sac or endodermal sinus tumor - choriocarcinoma b) embryonal ecto-, meso-, endodermal origin tissues represented -teratoma c) embryonal carcinoma Gonadal germ cells and stroma tumor (Sertoli and Leydig cells) Epithelial cells (ovarian origin) and granulosa cell tumor or mixted form as well as epithelial cell tumors more common in adults
Slide 51-

Clinical symptoms Testicular GCT :scrotal enlargement,hydrocele Ovarian tumors: abdominal pain, acute abdomen, abdominal mass Extragonadal GCT: main sites of involvement: -sacrococcygeal: t.1- (47%) predominantly external, t.2 -both external and intrapelvic t.3 -external, pelvix and abdominal t.4 –entitely presacral, -mediastinal (dyspnea, wheezing, thoracic pain, superior vena cava syndrome), -intracranial (visual disturbances, diabetes insipidus, hypopituitarism, anorexia, precocious puberty)
Slide 52-

Ovarian and testicular GCT
Slide 53-

Sacrococcygeal tumor in newborn
Slide 54-

Diagnostics Radiological diagnosis: ultrasound, computed tomography or magnetic resonance imaging Tumor markers: alpha-fetoprotein (AFP)- globulin produced in the fetal yolk sac, in embryonal hepatocytes and in gastrointestinal tract. Increase in malignant GCT, hepatoblastoma Newborns 48,000+/-34,000IU Up to 1 month 9,000+/-12,000 Up to 2 months 320 +/-280 Up to 4 months 74 +/-56 Up to 6 months 12+/-10 Up to 8 months 8+/-5 beta -human chorionic gonadotropin (HCG) – increase in germinoma/ dysgerminoma, choriocarcinoma
Slide 55-

Therapy Depend on: stage, location, tumor markers level Surgery in stage I Advanced stages: chemotherapy, surgery, radiotherapy Survival 95% - sacrococcygeal teratoma 80% -yolk sac tumor
Slide 56-

Wilms’ tumor Nephroblastoma
Slide 57-

Malignant embryonal tumor of renal tissue consisting of varying proportion of blastema, stroma and epithelium Epidemiology: 6% of all neoplasms in children 80 % of children at diagnosis are less than 5 years old peak incidence between 2nd and 3rd year of age - incidence slightly higher in boys
Slide 58-

Genetics Chromosomal association: Chromosome 11p13 with Wilms tumor suppressor gene WT1 in 10-30% of nephroblastoma Chromosome 11p15 with Wilms tumor suppressor gene WT2 Chromosome 17q with familial FWT-2 Association with congenital anomalies: -WAGR syndrome: Wilms tumor, aniridia, genital malformation, mental retardation) -Denys+Drash syndrome – pseudohermaphroditism, glomerulopathy, mutation on chromosome 11p -Beckwith Wiedemann syndrome- hemihypertrophy, macroglossia, omphalocele, visceromegaly, associated with WT2
Slide 59-

Clinical manifestation Abdominal mass- visible and/or palpable - 70%. Palpation must be done with care – risk of tumor rupture or dissemination! Fever Vomiting, anorexia Hematuria (micro or macro) 20-25% Hypertension in renin-producing tumors Pain 44% Special symptoms in association with congenital anomalies
Slide 60-

Laboratory diagnosis Urine: hematuria Chemistry: high serum calcium in children with rhabdoid nephroblastoma Acquired von Willebrand coagulopathy in about 8% of patients Differential diagnosis of NBL: 24-h urine catecholamine analysis Biopsy – only in children with unclear presentation or diagnosis
Slide 61-

The child with Wilms tumor
Slide 62-

Radiological diagnosis Ultrasound Computed tomography Magnetic resonance imaging =anatomy of tumor extend of any spread within abdomen Metastases: Chest radiographs (posteroanterior and lateral) to exclude pulmonary metastases Angiography may be indicated in bilateral nephroblastoma Radioisotope scans , skeletal survey in patients with suspected skeletal metastates CNS MRI in clear-cell sarcoma or rhabdoid kidney sarcoma and in patients with possible brain metastases
Slide 63-

Wilms tumor – pulmonary metastatic disease
Slide 64-

Wilms tumor – intraoperative view
Slide 65-

Prognostic factors Histological appearance „ favourable, unfavourable” Histology: rhabdoid tumor Diffuse anaplasia Viable malignant cells after preoperative chemotherapy Infiltration of tumor capsule Invasion of tumor cells into vessels Nonradical surgical resection of tumor Lymph nodes involvement Tumor rupture Metastatic spread Large tumor volume
Slide 66-

Stage National Wilms’ Tumor Study Group staging system I – tumor confined to the kidney and completely resected II- tumor extend beyond the kidney but is completely resected (none at margins, no lymph nodes). At least one of the following has occured: a) penetration of the renal capsule b) invasion of the renal sinus vessels c)biopsy of tumor before removal III- gross or microscopic residual tumor remains postoperatively including inoperable tumor, tumor at surgical margins, tumor spillage involving peritoneal surfaces, regional lymph node metastases or transected tumor thrombus IV- hematogenous metastases or lymph node metastases outside the abdomen (lung, liver, bone, brain) V – bilateral renal Wilms’tumor at onset
Slide 67-

Treatment Preoperative chemotherapy > surgery> postoperative chemotherapy with or without radiotherapy Primary surgery in infants less than 6 months old and in adolescents (>15years) Prognosis I stage 3year EFS 90% II 85% III 82% IV 58%